5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Sonoma Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Mar. 2023 was 266.06%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sonoma Pharmaceuticals's 5-Year ROIIC % or its related term are showing as below:
SNOA's 5-Year ROIIC % is ranked better than 96.59% of 998
companies
in the Drug Manufacturers industry
Industry Median: 3.62
vs SNOA: 266.06
Sonoma Pharmaceuticals 5-Year ROIIC % Historical Data
The historical data trend for Sonoma Pharmaceuticals's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sonoma Pharmaceuticals's 5-Year ROIIC %
For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonoma Pharmaceuticals's 5-Year ROIIC % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sonoma Pharmaceuticals's 5-Year ROIIC % falls into.
Sonoma Pharmaceuticals 5-Year ROIIC % Calculation
Sonoma Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Mar. 2023 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sonoma Pharmaceuticals 5-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Business Description
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNOA has been successfully added to your 